Sign In
OVAS.US
id: 277
It is still possible to file a late claim. The court will decide whether to accept late claims or not.
D. Massachusetts
Court
17 Dec 2014
Class period Start
28 Sept 2015
Class period End
22 Feb 2022
Claim deadline
Dahhan v. OvaScience, Inc., et al.
"Among other things, the Complaint alleges that, during the Class Period, the OvaScience Defendants knowingly or recklessly misrepresented and concealed material facts regarding the efficacy and commercial viability of AUGMENT. More specifically, the Complaint alleges that throughout the Class Period, the OvaScience Defendants made numerous public statements that led investors to believe that AUGMENT worked, and that there was significant demand from patients, which caused OvaScience’s common stock to allegedly trade at artificially inflated prices during the Class Period. The Complaint further alleges that the price of OvaScience stock declined when the true facts concerning the OvaScience Defendants’ alleged misrepresentations and omissions were revealed, resulting in financial losses to those who purchased or acquired OvaScience common stock during the Class Period at the inflated prices."
Case Status
Accepting Late Claims
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Plaintiffs
Reedman Family Investments LLC
Attorneys
Robbins Geller Rudman & Dowd LLP
Judge
Hon. Indira Talwani
Administrator
Gilardi & Co LLC
Court hearing date
26 July 2022
+$15,000,000
Cash Settlement Amount

OvaScience Inc.

As of December 7, 2018, OvaScience, Inc. was acquired by Millendo Therapeutics, Inc., in a reverse merger transaction. OvaScience, Inc., a fertility company, discovers, develops, and commercializes...

    Ticker
    OVAS.US
    ISIN
    US69014Q1013
    Sector
    Other
    Industry
    Other
    Country
    USA
    Address
    9 4th Avenue 02451,Waltham,USA